Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Trastornos del Movimiento

3520 ARTÍCULOS , VIENDO DEL 1921 AL 1935

Is alpha-synuclein in the colon a biomarker for premotor Parkinson's disease? Evidence from 3 cases

Shannon KM, Keshavarzian A, Dodiya HB, Jakate S, Kordower JH.

Mov Disord. 2012 May;27(6):716-9. doi: 10.1002/mds.25020. Epub 2012 May 1.

Sleep disturbances in Alzheimer's and Parkinson's diseases

Rothman SM, Mattson MP.

Neuromolecular Med. 2012 Sep;14(3):194-204. doi: 10.1007/s12017-012-8181-2. Epub 2012 May 3.

Functional neuroimaging in Parkinson's disease

Niethammer M, Feigin A, Eidelberg D.

Cold Spring Harb Perspect Med. 2012 May;2(5):a009274. doi: 10.1101/cshperspect.a009274.

Disruption of protein quality control in Parkinson's disease

Cook C, Stetler C, Petrucelli L.

Cold Spring Harb Perspect Med. 2012 May;2(5):a009423. doi: 10.1101/cshperspect.a009423.

Orthosteric versus allosteric GPCR activation: the great challenge of group-III mGluRs

Flor PJ, Acher FC.

Biochem Pharmacol. 2012 Aug 15;84(4):414-24. doi: 10.1016/j.bcp.2012.04.013. Epub 2012 Apr 24.

Lewy body pathology and typical Parkinson disease in a patient with a heterozygous (R275W) mutation in the Parkin gene (PARK2)

Ruffmann C, Zini M, Goldwurm S, Bramerio M, Spinello S, Rusconi D, Gambacorta M, Tagliavini F, Pezzoli G, Giaccone G.

Acta Neuropathol. 2012 Jun;123(6):901-3. doi: 10.1007/s00401-012-0991-7. Epub 2012 May 4.

Effect of deep brain stimulation on postencephalitic parkinsonism: a case report

Hu SC, Hebb AO.

Mov Disord. 2012 Jul;27(8):1071-2. doi: 10.1002/mds.25014. Epub 2012 May 3.

[Current strategies for the treatment of Parkinson's disease]

Wolters A, Benecke R.

MMW Fortschr Med. 2012 Apr 19;154(7):59-62.

What can we expect from the serotonergic side of L-DOPA?

De Deurwaerdère P, Navailles S.

Rev Neurol (Paris). 2012 Dec;168(12):927-38. doi: 10.1016/j.neurol.2012.01.585. Epub 2012 May 2.

From α-synuclein to synaptic dysfunctions: new insights into the pathophysiology of Parkinson's disease

Bellucci A, Zaltieri M, Navarria L, Grigoletto J, Missale C, Spano P.

Brain Res. 2012 Oct 2;1476:183-202. doi: 10.1016/j.brainres.2012.04.014. Epub 2012 Apr 17.

Combined beneficial effect of rasagiline on motor function and depression in de novo PD

Korchounov A, Winter Y, Rössy W.

Clin Neuropharmacol. 2012 May-Jun;35(3):121-4. doi: 10.1097/WNF.0b013e31823b1da8.

Neurogenic orthostatic hypotension as the initial feature of Parkinson disease

Milazzo V, Di Stefano C, Servo S, Zibetti M, Lopiano L, Maule S.

Clin Auton Res. 2012 Aug;22(4):203-6. doi: 10.1007/s10286-012-0165-7. Epub 2012 May 5.

A deleterious mutation in DNAJC6 encoding the neuronal-specific clathrin-uncoating co-chaperone auxilin, is associated with juvenile parkinsonism

Edvardson S, Cinnamon Y, Ta-Shma A, Shaag A, Yim YI, Zenvirt S, Jalas C, Lesage S, Brice A, Taraboulos A, Kaestner KH, Greene LE, Elpeleg O.

PLoS One. 2012;7(5):e36458. doi: 10.1371/journal.pone.0036458. Epub 2012 May 1.

Analysis of attitudes toward the source of progenitor cells in tissue-engineered products for use in burns compared with other disease states

Clover AJ, O'Neill BL, Kumar AH.

Wound Repair Regen. 2012 May-Jun;20(3):311-6. doi: 10.1111/j.1524-475X.2012.00779.x.

The pharmacological properties and therapeutic use of apomorphine

Ribarič S.

Molecules. 2012 May 7;17(5):5289-309. doi: 10.3390/molecules17055289.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias